Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 102, showing 5 Applications out of 509 total, starting on record 16, ending on 20

# Protocol No Study Title Investigator(s) & Site(s)

16.

ECCT/24/11/01   Sparkle
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
1. Site 1401:Victoria Biomedical Research Institute (Kisumu county)
2. Site 1402:Ahero Clinical trials Unit (Kisumu county)
3. Site 1403:International Cancer institute (Uasin Gishu county)
4. Site 1404:Kondele Childrens Hospital (Kisumu county)
5. Site 1405:KEMRI/CRDR KEMRI Clinical Research Annex (Kisumu county)
6. Site 1406:Gertrudes Children’s Hospital (Nairobi City county)
 
View

17.

ECCT/24/10/04   Cabotegravir + Rilpivirine Inj
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project Clinical Research Centre (Kericho county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Aga Khan University Hospital Nairobi (Nairobi City county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
View

18.

ECCT/24/10/02   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Isaac Tsikhutsu
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project, Clinical Research Center (Kericho county)
 
View

19.

ECCT/24/10/01   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Videlis Nduba Nzioka
Site(s) in Kenya
1. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
2. Clinical Research Health Network (CREA-N) (Machakos county)
3. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
4. KEMRI-Mtwapa Clinical Annex (Kilifi county)
5. University of Nairobi Clinical Research Centre (Nairobi City county)
 
View

20.

ECCT/24/10/03   EDE Scanner Study
    A non-interventional clinical validation study of the Exponential Deep Examination (EDE) scanner in the detection of human immunodeficiency virus (HIV), tuberculosis (TB) and malaria   
Principal Investigator(s)
1. VIDELIS Nduba
2. Berngards Ogutu
Site(s) in Kenya
1. Ahero Clinical Trials Unit (Kisumu county)
2. KEMRI/CRDR Siaya Clinical trials Annex (Siaya county)
3. VICTORIA BIOMEDICAL RESEARCH INSTITUTE (Kisumu county)
 
View